nach oben

Current Cardiology Reports

Erschienen in:

27.01.2022 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths

verfasst von: Jose B. Cruz Rodriguez, Khan O. Mohammad, Haider Alkhateeb

Erschienen in: Current Cardiology Reports | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Explore the current literature supporting risk stratification scores for prediction of coronary and cardiovascular disease deaths.

Recent Findings

Accurate risk prediction remains the foundation of management choice in primary prevention. When applied to new populations, the calibration of a predictive model will deteriorate, although discrimination changes minimally. One of the approaches with better performance and validation is the initial use of pooled cohort equation to identify low and high-risk patients, followed by coronary artery calcium scoring in those with borderline to intermediate risk.

Summary

It is important to utilize a risk stratification tool that has been validated in a patient population that resembles the one used to develop the original tool to maintain adequate calibration. It is likely that the future of mortality risk prediction will develop in combined clinical risk predictors and cardiovascular imaging, such coronary artery calcium (CAC) scoring that renders the highest predictive accuracy.

Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr Opin Lipidol. 2006;17:375–86. https://doi.org/10.1097/01.mol.0000236362.56216.44.CrossRefPubMed

Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752–9. https://doi.org/10.1136/hrt.2006.087932.CrossRefPubMedPubMedCentral

Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25(4):1692–706. https://doi.org/10.1177/0962280213497434.CrossRefPubMed

Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052–6. https://doi.org/10.1097/01.CCM.0000275267.64078.B0.CrossRefPubMed

Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 2010;14(2):207. https://doi.org/10.1186/cc8204.CrossRefPubMedPubMedCentral

Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008. https://doi.org/10.1016/S0140-6736(13)61752-3.CrossRefPubMed

British Cardiac Society. JBS 2: joint British societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91:v1–52. https://doi.org/10.1136/hrt.2005.079988.CrossRef

Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–10. https://doi.org/10.1136/bmj.320.7236.709.CrossRefPubMedPubMedCentral

D’agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–53. https://doi.org/10.1161/CIRCULATIONAHA.107.699579.CrossRefPubMed

10.

Rabanal KS, Meyer HE, Pylypchuk R, Mehta S, Selmer RM, Jackson RT. Performance of a Framingham cardiovascular risk model among Indians and Europeans in New Zealand and the role of body mass index and social deprivation. Open Heart. 2018;5(2):e000821. https://doi.org/10.1136/openhrt-2018-000821.CrossRefPubMedPubMedCentral

11.

Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327(7426):1267. https://doi.org/10.1136/bmj.327.7426.1267.CrossRefPubMedPubMedCentral

12.

Asia Pacific Cohort Studies Collaboration, Barzi F, Patel A, Gu D, Sritara P, Lam TH, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61(2):115–21. https://doi.org/10.1136/jech.2005.044842.

13.

Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup population studies and Framingham Heart Study. Int J Epidemiol. 2002;31(4):817–22. https://doi.org/10.1093/ije/31.4.817.CrossRefPubMed

14.

Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany–results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24(10):937–45. https://doi.org/10.1016/s0195-668x(03)00081-2.CrossRefPubMed

15.

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. https://doi.org/10.1016/s0195-668x(03)00114-3.

16.

Thomsen T. HeartScore: a new web-based approach to European cardiovascular disease risk management. Eur J Cardiovasc Prev Rehabil. 2005;12(5):424–6. https://doi.org/10.1097/01.hjr.0000186617.29992.11 (PMID: 16210927).

17.

Courand PY, Lenoir J, Grandjean A, Garcia D, Harbaoui B, Lantelme P. SCORE underestimates cardiovascular mortality in hypertension: insight from the OLD-HTA and NEW-HTA Lyon cohorts. Eur J Prev Cardiol. 2021 Jan 18:zwaa163. https://doi.org/10.1093/eurjpc/zwaa163.

18.

Goh LG, Welborn TA, Dhaliwal SS. Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study. BMC Womens Health. 2014;26(14):118. https://doi.org/10.1186/1472-6874-14-118.CrossRef

19.

Selvarajah S, Kaur G, Haniff J, Cheong KC, Hiong TG, van der Graaf Y, et al. Comparison of the Framingham risk score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol. 2014;176(1):211–8. https://doi.org/10.1016/j.ijcard.2014.07.066.CrossRefPubMed

20.

Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73. https://doi.org/10.1161/01.cir.0000437741.48606.98.

21.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;2019(74):e177-232. https://doi.org/10.1016/j.jacc.2019.03.010.CrossRef

22.

The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.Am J Epidemiol. 1989;129:687–702.

23.

Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The cardiovascular health study: design and rationale. Ann Epidemiol. 1991;1(3):263–76. https://doi.org/10.1016/1047-2797(91)90005-w.CrossRefPubMed

24.

Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41(11):1105–16. https://doi.org/10.1016/0895-4356(88)90080-7.CrossRefPubMed

25.

Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110(3):281–90. https://doi.org/10.1093/oxfordjournals.aje.a112813

26.

Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959. https://doi.org/10.1016/j.jacc.2013.11.005.

27.

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-743. https://doi.org/10.1161/CIR.0000000000000950.CrossRefPubMed

28.

Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311(14):1406–15. https://doi.org/10.1001/jama.2014.2630.CrossRefPubMedPubMedCentral

29.

Golabi P, Fukui N, Paik J, Sayiner M, Mishra A, Younossi ZM. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2019;3(8):1050–60. https://doi.org/10.1002/hep4.1387.CrossRefPubMedPubMedCentral

30.

Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–9. https://doi.org/10.1001/jama.297.6.611.CrossRefPubMed

31.

Ambale-Venkatesh B, Yang X, Wu CO, Liu K, Hundley WG, McClelland R, et al. Cardiovascular event prediction by machine learning: the multi-ethnic study of atherosclerosis. Circ Res. 2017;121(9):1092–101. https://doi.org/10.1161/CIRCRESAHA.117.311312.CrossRefPubMedPubMedCentral

32.

Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–45. https://doi.org/10.1056/NEJMoa072100.CrossRefPubMed

33.

Möhlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, et al. Heinz Nixdorf Recall Study Investigators. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–64. https://doi.org/10.1016/j.jacc.2010.10.043.

34.

Blaha MJ, Whelton SP, Al Rifai M, Dardari ZA, Shaw LJ, Al-Mallah MH, et al. Rationale and design of the coronary artery calcium consortium: a multicenter cohort study. J Cardiovasc Comput Tomogr. 2017;11:54–61. https://doi.org/10.1016/j.jcct.2016.11.004.CrossRefPubMed

35.

•• Wang FM, Rozanski A, Arnson Y, Budoff MJ, Miedema MD, Nasir K, et al. Cardiovascular and all-cause mortality risk by coronary artery calcium scores and percentiles among older adult males and females. Am J Med. 2021;134(3):341–50. https://doi.org/10.1016/j.amjmed.2020.07.024. Recent analysis of additive value in CAC for risk prediction.CrossRefPubMed

36.

Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open. 2014;4(5): e005025. https://doi.org/10.1136/bmjopen-2014-005025.CrossRefPubMedPubMedCentral

37.

Orimoloye OA, Banga S, Dardari ZA, Uddin SMI, Budoff MJ, Berman DS, et al. Coronary artery calcium as a predictor of coronary heart disease, cardiovascular disease, and all-cause mortality in Asian-Americans: The Coronary Artery Calcium Consortium. Coron Artery Dis. 2019;30(8):608–14. https://doi.org/10.1097/MCA.0000000000000746.CrossRefPubMedPubMedCentral

38.

Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol. 2017;2(6):635–43. https://doi.org/10.1001/jamacardio.2017.0363.CrossRefPubMedPubMedCentral

39.

Xie Q, Ge X, Shang D, Li Y, Yan H, Tian J, et al. Coronary artery calcification score as a predictor of all-cause mortality and cardiovascular outcome in peritoneal dialysis patients. Perit Dial Int. 2016;36(2):163–70. https://doi.org/10.3747/pdi.2014.00124.

40.

Whelton SP, Al Rifai M, Dardari Z, Shaw LJ, Al-Mallah MH, Matsushita K, et al. Coronary artery calcium and the competing long-term risk of cardiovascular vs. cancer mortality: the CAC Consortium. Eur Heart J Cardiovasc Imaging. 2019;20(4):389–395. https://doi.org/10.1093/ehjci/jey176.

41.

Shaikh K, Li D, Nakanishi R, Kinninger A, Almeida S, Cherukuri L, et al. Low short-term and long-term cardiovascular and all-cause mortality in absence of coronary artery calcium: a 22-year follow-up observational study from large cohort. J Diabetes Complications. 2019;33(9):616–22. https://doi.org/10.1016/j.jdiacomp.2019.05.015.CrossRefPubMed

42.

Yamamoto H, Kitagawa T, Kunita E, Utsunomiya H, Senoo A, Nakamoto, et al. Impact of the coronary artery calcium score on mid- to long-term cardiovascular mortality and morbidity measured with coronary computed tomography angiography. Circ J. 2018;82(9):2342–2349. https://doi.org/10.1253/circj.CJ-18-0086.

43.

Dudum R, Dzaye O, Mirbolouk M, Dardari ZA, Orimoloye OA, Budoff MJ, et al. Coronary artery calcium scoring in low risk patients with family history of coronary heart disease: validation of the SCCT guideline approach in the coronary artery calcium consortium. J Cardiovasc Comput Tomogr. 2019;13(3):21–25. https://doi.org/10.1016/j.jcct.2019.03.012.

44.

•• Blaha MJ, Whelton SP, Al Rifai M, Dardari Z, Shaw LJ, Al-Mallah MH, et al. Comparing risk scores in the prediction of coronary and cardiovascular deaths: coronary artery calcium consortium. Cardiovascular Imaging. 2021;14(2):411–21. https://doi.org/10.1016/j.jcmg.2019.12.010. Direct comparison of three risk scores for coronary and CVD deaths.CrossRefPubMed

45.

Shaw LJ, Min JK, Nasir K, Xie JX, Berman DS, Miedema MD, et al. Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. Eur Heart J. 2018;39(41):3727–35. https://doi.org/10.1093/eurheartj/ehy534.CrossRefPubMedPubMedCentral

46.

Liew G, Chow C, van Pelt N, Younger J, Jelinek M, Chan J, et al. Cardiac Society of Australia and New Zealand position statement: coronary artery calcium scoring. Heart Lung Circ. 2017;26(12):1239–51. https://doi.org/10.1016/j.hlc.2017.05.130.CrossRefPubMed

47.

Savic L, Mrdovic I, Asanin M, Stankovic S, Krljanac G, Lasica R. Using the RISK-PCI score in the long-term prediction of major adverse cardiovascular events and mortality after primary percutaneous coronary intervention. J Interv Cardiol. 2019;24(2019):2679791. https://doi.org/10.1155/2019/2679791.CrossRef

48.

Mrdovic I, Savic L, Krljanac G, Asanin M, Perunicic J, Lasica R, et al. Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. Int J Cardiol. 2013;162(3):220–7. https://doi.org/10.1016/j.ijcard.2011.05.071.

49.

Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. https://doi.org/10.1136/bmj.38985.646481.55.CrossRefPubMedPubMedCentral

50.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-228. https://doi.org/10.1016/j.jacc.2014.09.017.CrossRefPubMed

51.

Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–367. https://doi.org/10.1093/eurheartj/ehaa575.CrossRefPubMed

52.

Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165–75. https://doi.org/10.1056/NEJMoa0807986.CrossRefPubMed

53.

Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome: VERDICT randomized controlled trial. Circulation. 2018;138(24):2741–50. https://doi.org/10.1161/CIRCULATIONAHA.118.037152.CrossRefPubMed

54.

Huang W, FitzGerald G, Goldberg RJ, Gore J, McManus RH, Awad H, et al. Performance of the GRACE risk score 2.0 simplified algorithm for predicting 1-year death after hospitalization for an acute coronary syndrome in a contemporary multiracial cohort. Am J Cardiol. 2016;118(8):1105–10. https://doi.org/10.1016/j.amjcard.2016.07.029

55.

Fox KA, FitzGerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2): e004425. https://doi.org/10.1136/bmjopen-2013-004425.CrossRefPubMedPubMedCentral

56.

Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–601. https://doi.org/10.1161/01.cir.100.15.1593.CrossRefPubMed

57.

Poldervaart JM, Langedijk M, Backus BE, Dekker IM, Six AJ, Doevendans PA, et al. Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department. Int J Cardiol. 2017;15(227):656–61. https://doi.org/10.1016/j.ijcard.2016.10.080.CrossRef

58.

Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.

59.

Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293(5):572–80. https://doi.org/10.1001/jama.293.5.572.

60.

Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, et al. American Heart Association get with the guidelines-heart failure program. a validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25–32. https://doi.org/10.1161/CIRCOUTCOMES.109.854877.

61.

Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75. https://doi.org/10.1093/eurheartj/ehi555.CrossRefPubMed

62.

Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle heart failure model. Circulation. 2006;113(11):1424–33. https://doi.org/10.1161/CIRCULATIONAHA.105.584102.CrossRefPubMed

63.

Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–7. https://doi.org/10.1001/jama.290.19.2581.CrossRefPubMed

64.

Rich JD, Burns J, Freed BH, Maurer MS, Burkhoff D, Shah SJ. Meta-analysis global group in chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction. J Am Heart Assoc. 2018;7(20): e009594. https://doi.org/10.1161/JAHA.118.009594.CrossRefPubMedPubMedCentral

65.

Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870–6. https://doi.org/10.1016/j.amjcard.2012.05.014.CrossRefPubMedPubMedCentral

66.

Shah SJ. Innovative clinical trial designs for precision medicine in heart failure with preserved ejection fraction. J Cardiovasc Transl Res. 2017;10:322–36. https://doi.org/10.1007/s12265-017-9759-8.CrossRefPubMedPubMedCentral

67.

Khan SS, Ning H, Shah SJ, Yancy CW, Carnethon M, Berry JD, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388–97. https://doi.org/10.1016/j.jacc.2019.02.057.CrossRefPubMedPubMedCentral

68.

Razavi AC, Potts KS, Kelly TN, He J, Fernandez C, Krousel-Wood M, et al. Pooled cohort equations heart failure risk score predicts cardiovascular disease and all-cause mortality in a nationally representative sample of US adults. BMC Cardiovasc Disord. 2020;20(1):202. https://doi.org/10.1186/s12872-020-01485-2.CrossRefPubMedPubMedCentral

69.

Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27(16):1979–2030. https://doi.org/10.1093/eurheartj/ehl176.

70.

Vodošek Hojs N, Ekart R, Bevc S, Piko N, Hojs R. CHA2DS2-VASc score as a predictor of cardiovascular and all-cause mortality in chronic kidney disease patients. Am J Nephrol. 2021;11:1–8. https://doi.org/10.1159/000516121.CrossRef

71.

Schamroth Pravda M, Cohen Hagai K, Topaz G, Schamroth Pravda N, Makhoul N, Shuvy M, et al. Assessment of the CHA2DS2-VASc score in predicting mortality and adverse cardiovascular outcomes of patients on hemodialysis. Am J Nephrol. 2020;51(8):635–40. https://doi.org/10.1159/000508836.CrossRefPubMed

72.

Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107(6):912–6. https://doi.org/10.1016/j.amjcard.2010.10.074.CrossRefPubMed

73.

Ruwald MH, Ruwald AC, Jons C, Lamberts M, Hansen ML, Vinther M, et al. Evaluation of the CHADS2 risk score on short- and long-term all-cause and cardiovascular mortality after syncope. Clin Cardiol. 2013;36(5):262–8. https://doi.org/10.1002/clc.22102.CrossRefPubMedPubMedCentral

74.

Shuvy M, Klein E, Cohen T, Shlomo N, Rozenbaum Z, Pereg D. Value of adding the CHA2DS2-VASc score to the GRACE score for mortality risk prediction in patients with acute coronary syndrome. Am J Cardiol. 2019;123(11):1751–6. https://doi.org/10.1016/j.amjcard.2019.02.045.CrossRefPubMed

75.

Ivanovs R, Kivite A, Ziedonis D, Mintale I, Vrublevska J, Rancans E. Association of depression and anxiety with the 10-year risk of cardiovascular mortality in a primary care population of Latvia using the SCORE system. Front Psychiatry. 2018;26(9):276. https://doi.org/10.3389/fpsyt.2018.00276.CrossRef

76.

O’Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, et al. Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J. 2012;33(14):1777–86. https://doi.org/10.1093/eurheartj/ehs053.CrossRefPubMed

77.

Kerola T, Hiltunen M, Kettunen R, Hartikainen S, Sulkava R, Vuolteenaho O, et al. Mini-mental state examination score and B-type natriuretic peptide as predictors of cardiovascular and total mortality in an elderly general population. Ann Med. 2011;43(8):650–9. https://doi.org/10.3109/07853890.2010.526137.CrossRefPubMed

78.

Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review. Crit Care. 2008;12(6):R161. https://doi.org/10.1186/cc7160.CrossRefPubMedPubMedCentral

79.

Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE). Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA. 2017;317(3):290–300. https://doi.org/10.1001/jama.2016.20328.

80.

Aoyama D, Morishita T, Uzui H, Miyazaki S, Ishida K, Kaseno K, et al. Sequential organ failure assessment score on admission predicts long-term mortality in acute heart failure patients. ESC Heart Fail. 2020;7(1):244–52. https://doi.org/10.1002/ehf2.12563.CrossRefPubMedPubMedCentral

81.

Jentzer JC, Bennett C, Wiley BM, Murphree DH, Keegan MT, Barsness GW. Predictive value of individual sequential organ failure assessment sub-scores for mortality in the cardiac intensive care unit. PLoS One. 2019;14(5): e0216177. https://doi.org/10.1371/journal.pone.0216177.CrossRefPubMedPubMedCentral

82.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136. https://doi.org/10.1136/bmj.39261.471806.55.CrossRefPubMedPubMedCentral

83.

Woodward M, Brindle P, Tunstall-Pedoe H. for the SIGN Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish heart health extended cohort (SHHEC). Heart. 2007;93:172–176. https://doi.org/10.1136/hrt.2006.108167.

84.

Schulte H, Cullen P, Assmann G. Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis. 1999;144(1):199–209. https://doi.org/10.1016/s0021-9150(99)00055-6.CrossRefPubMed

85.

Versteylen MO, Joosen IA, Shaw LJ, Narula J, Hofstra L. Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events. J Nucl Cardiol. 2011;18(5):904–11. https://doi.org/10.1007/s12350-011-9425-5.CrossRefPubMedPubMedCentral

86.

D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7. https://doi.org/10.1001/jama.286.2.180.

87.

Fernández-Torres R, Pita-Fernández S, Fonseca E. Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 2013;27(12):1566–70. https://doi.org/10.1111/j.1468-3083.2012.04618.x.

88.

Anderson JL, Ronnow BS, Horne BD, Carlquist JF, May HT, Bair TL, et al. Intermountain Heart Collaborative (IHC) Study Group. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol. 2007;99(2):169–74. https://doi.org/10.1016/j.amjcard.2006.08.015.

89.

Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323(7304):75–81. https://doi.org/10.1136/bmj.323.7304.75.CrossRefPubMedPubMedCentral

90.

Sotos-Prieto M, Mattei J, Cook NR, Hu FB, Willett WC, Chiuve SE, et al. Association between a 20-year cardiovascular disease risk score based on modifiable lifestyles and total and cause-specific mortality among US men and women. J Am Heart Assoc. 2018;7(21): e010052. https://doi.org/10.1161/JAHA.118.010052.CrossRefPubMedPubMedCentral

91.

Wohlfahrt P, Bruthans J, Krajčoviechová A, Šulc P, Linhart A, Filipovský J, et al. Systematic coronary risk evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. Eur J Intern Med. 2020;79:63–9. https://doi.org/10.1016/j.ejim.2020.05.034.CrossRefPubMed

Titel: Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths
verfasst von: Jose B. Cruz Rodriguez
Khan O. Mohammad
Haider Alkhateeb
Publikationsdatum: 27.01.2022
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 1/2022
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-021-01620-1

Pseudopheochromocytoma: an Uncommon Cause of Severe Hypertension

Hypertension (DS Geller and DL Cohen, Section Editors)

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis

New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

Treatment of Bicuspid Aortic Valve Stenosis with TAVR: Filling Knowledge Gaps Towards Reducing Complications

Valvular Heart Disease (TL Kiefer, Section Editor)

Updates in Cerebral Venous Thrombosis

Stroke (DL Tirschwell, Section Editor)

Cardiac Outpatient Care in a Digital Age: Remote Cardiology Clinic Visits in the Era of COVID-19

Zur Zeit gratis
COVID-19
Ischemic Heart Disease (D Mukherjee, Section Editor)

Covered Stents in the Management of Aortic Coarctation and Right Ventricular Outflow Tract Obstruction

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

20.01.2025
Koronare Herzerkrankung
Nachrichten

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

20.01.2025
Chronische Herzinsuffizienz
Nachrichten

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

LVAD auch bei kalt-trockener terminaler Herzinsuffizienz wirksam

20.01.2025
Herzinsuffizienz
Nachrichten

Auch Personen mit kalt-trockener terminaler Herzinsuffizienz profitieren von einem linksventrikulären Unterstützungssystem (LVAD), wie Daten aus einem US-Register nahelegen. Doch es gibt Besonderheiten.

Koronare Herzkrankheit: Das waren die Top-Studien 2024

12.01.2025
Koronare Herzerkrankung
Nachrichten

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 1/2022

Pseudopheochromocytoma: an Uncommon Cause of Severe Hypertension

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis

Treatment of Bicuspid Aortic Valve Stenosis with TAVR: Filling Knowledge Gaps Towards Reducing Complications

Updates in Cerebral Venous Thrombosis

Cardiac Outpatient Care in a Digital Age: Remote Cardiology Clinic Visits in the Era of COVID-19

Covered Stents in the Management of Aortic Coarctation and Right Ventricular Outflow Tract Obstruction

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Kardiologie

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Finerenon bei eGFR-Verlust nicht gleich absetzen!

LVAD auch bei kalt-trockener terminaler Herzinsuffizienz wirksam

Koronare Herzkrankheit: Das waren die Top-Studien 2024

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten